Co-Founder & CEO
With more than 10 years of experience, Mark is a passionate expert in biopharmaceutical process development. He worked together with several Top25 pharma companies in different projects, targeting their process development and understanding needs. After his Ph.D in bioprocess engineering he decided to found Novasign together with other dedicated scientists to speed up bioprocess development using advanced machine learning tools. Within Novasign, he develops a hybrid modeling software for both up and downstream processes together with his team. This software utilizes AI applied to process data and first principle models (hybrid models) to faster and better predict critical quality attributes (CQAs) from critical process parameters (CPPs). Hereby, bioprocess development and characterization are accelerated significantly while a better process understanding is gathered.